Lilly Leverages Its Revenue Advantage To ‘Play Offense’ In Deals Sphere
With industry-leading sales growth driven by the tirzepatide franchise, Lilly is lapping the competition in dealmaking. Its lack of a patent cliff allows it to embrace risk and make larger acquisitions without having to “buy revenue.”
Scrip - August 3, 2026

Sobi CEO Guido Oelkers Will Lead BioNTech’s Transition To Oncology Player
BioNTech’s new CEO brings a strong track record at Swedish Orphan Biovitrum (Sobi) since 2017; the Swedish firm said it will begin a search for a successor.
Scrip - August 3, 2026

Supernus/Indivior Merge As CNS-Focused Biopharma Led By Soblocade
The combined company will have $2.2bn in revenues coming from a portfolio of commercial products and will be called Supernus, led by Supernus CEO Jack Khattar.
Scrip - August 3, 2026

Rocket Pushes Ahead After Successful Safety Results In Danon Disease Trial
The company said patients dosed with RP-A501 under a modified trial protocol did not experience thrombotic microangiopathy or capillary leak syndrome.
Scrip - August 3, 2026

AstraZeneca/BMS Merger Would Be Biopharma’s Biggest, By Far
Estimated at around $160bn, the rumored AstraZeneca/Bristol Myers Squibb merger would be biopharma’s largest ever. The sector has made 16 deals valued at $20bn+ over the last two decades, with five above $50bn.
Scrip - August 3, 2026

Curium To Buy Radiopharmaceutical Company Lantheus In Up To $8Bn Deal
Curium has agreed to acquire Lantheus Holdings for up to $8bn, adding a leading US radiodiagnostic platform including PYLARIFY and DEFINITY and Neuraceq to its portfolio. The deal is expected to close in H1 2027.
Medtech Insight - August 3, 2026

Siemens Healthineers Bets AI And Workflow Innovation Will Counter Diagnostic Woes
Siemens Healthineers cut revenue outlook on disappointing diagnostics sales, but highlighted new partnerships and AI-driven real-time imaging push.
Medtech Insight - August 3, 2026

Slow And Steady: FDA Chalks Up Two More Biosimilar Approvals
The US FDA has approved two more biosimilars in the form of Meitheal’s Garzulys (insulin aspart-fsan) rival to Novolog and the Fresenius Kabi and Dr Reddy’s partnered version of Rituxan (rituximab).
Generics Bulletin - August 3, 2026

Role Reversal: AstraZeneca Goes From Fighting Off Pfizer To Courting Bristol
Twelve years after spurning Pfizer, AstraZeneca's Pascal Soriot, according to reports, is weighing a mega-merger with Bristol Myers, potentially forming one of the world's biggest pharma firms with a combined value of about $400bn.
Scrip - August 3, 2026

Penumbra’s THUNDERBOLT Clears IDE Bar But Single-Arm Design Limits Claims
Penumbra's THUNDERBOLT system hit its reperfusion target with margin in the THUNDER IDE study, but the single-arm design and reliance on a predicate-derived benchmark leave some questions about how the numbers compare to existing devices.
Medtech Insight - August 3, 2026

UCB Bets On Next-Generation Pipeline To Sustain Growth Beyond Current Portfolio
UCB is building multiple future growth engines across immunology, neuroscience and regenerative assets, EVP Emmanuel Caeymaex tells Scrip.
Scrip - August 3, 2026

Pipeline Watch: Three Approvals And Six Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - August 3, 2026

Biocon’s Yesafili Launch Leads Second Wave Of Eylea Biosimilars
Biocon has launched its Yesafili biosimilar aflibercept rival to Eylea 2mg in the US, under a settlement with Regeneron. It will face both the originator brand and Amgen’s Pavblu version, ahead of anticipated imminent further competition from multiple other sponsors.
Generics Bulletin - August 3, 2026

Patch Approval Validates Viatris’ Drug-Device Development Capabilities
FDA approval of Gwyn Lo gives Viatris a differentiated, low-dose contraceptive patch and a near-term US launch, while advancing its push into women’s health and higher-value 505(b)(2) products.
Generics Bulletin - August 3, 2026

Sandoz Pays Heavily To Close US Price-Fixing Claims
Sandoz will pay about $478.5m to resolve remaining US government claims and its final pending class action, leaving only opt-out plaintiff cases while preserving its 2026 guidance.
Generics Bulletin - August 3, 2026

Sun Eyes Expanded Indications For Leqselvi And Unloxcyt, Wider Semaglutide Play
Leqselvi, Sun's JAK1/2 inhibitor for alopecia areata, surpassed 1,000 US prescribers and in June delivered its strongest sales month since launch. Sun is now weighing additional indications for the drug while its semaglutide franchise opens new fronts in South Africa and Brazil.
Scrip - August 3, 2026

CMR Surgical Banks On Portability And Open Data To Crack Da Vinci-Dominated Market
CMR Surgical is entering the US surgical robotics market with a counter-intuitive playbook: complement rather than displace incumbents, lead on portability, and build a data moat through an NVIDIA partnership — while Intuitive still owns the room.
Medtech Insight - August 3, 2026

Bristol-Zeneca? Industry May Be Poised For A Mega Merger
Bristol Myers Squibb and AstraZeneca are reported to be in merger discussions, a combination that would shake up the pharma sector.
Scrip - August 3, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: AstraZeneca reins in AI spending; Argenx’s pipeline in a product play; GSK cutting costs amid Phase III plans; Sanofi’s pipeline reckoning; and NewCo version 2 for Chinese assets.
Scrip - August 3, 2026